I am engaged in the development of diagnostic methods and the evaluation of the clinical significance of vasoinhibin, a vasoactive peptide hormone, which is produced by proteolytic cleavage of the pituitary hormone prolactin. The principle underlying the regulation and effects of vasoinhibin was first described by us as an endocrine axis in 2015, and named the prolactin/vasoinhibin axis. Clinical relevance, including drug intervention studies intervening in the prolactin/vasoinhibin axis, is demonstrated in diabetic retinopathy and diabetic macular edema, peripartum cardiomyopathy (heart failure that can occur in pregnant women), as well as in pregnancy hypertension (pre-eclampsia). The role of the prolactin/vasoinhibin axis in tumor diseases is predominantly investigated at the experimental stage and has not yet been translated to studies with patients.

Selected Publications

In this publication, the vasoinhibin nomenclature is explained and a compact overview of publications is shown which have been pathbreaking for the development of the field within the past 40 years: 

Triebel, J., et al. (2019). “Regulator of Angiogenesis and Vascular Function: A 2019 Update of the Vasoinhibin Nomenclature.” Front Endocrinol (Lausanne) 10: 214.

This publication is an overview of the advancements that have led to the development of clinical trials investigating drug intervention to suppress or stimulate the generation of vasoinhibin in patients:

Triebel, J., et al. (2017). “From Bench to Bedside: Translating the Prolactin/Vasoinhibin Axis.” Front Endocrinol (Lausanne) 8: 342.

In the following publication, the principles underlying the regulation and effects of vasoinhibin are described as an endocrine axis, the prolactin/vasoinhibin axis:

Triebel, J., et al. (2015). “Principles of the prolactin/vasoinhibin axis.” Am J Physiol Regul Integr Comp Physiol 309(10): R1193-1203.


Third place in the VIII edition of the Program for the Promotion of Patenting and Innovation (PROFOPI), with the technological development “Oligopeptides inhibiting angiogenesis and vascular function” Universidad Nacional Autónoma de México, 2020

Tercer lugar en la VIII edición del Programa para el Fomento al Patentamiento y la Innovación (PROFOPI), con es desarrollo tecnológico “Oligopéptidos inhibitorios de la angiogénesis y de la función vascular” Universidad Nacional Autónoma de México, 2020

Scientist of the Year 2017 in the Category „Theoretical Disciplines“
Science Price in Gold, 2018
Science Price in Silver, 2020
for excellent achievements in research and successful publishing, Paracelsus Medical University Nuremberg/Salzburg

San Francisco Declaration on Research Assessment
Ärzte Codex